Messenger ribonucleic acid (mRNA) technology, previously focused on infectious disease vaccines, is now making significant inroads into cancer treatment. Moderna has confirmed meaningful efficacy in a large-scale Phase 3 trial of its personalized mRNA cancer vaccine, indicating that mRNA could revolutionize cancer therapy.
On August 19, Moderna and Merck (MSD) announced the results of their Phase 3 trial involving 1,137 high-risk melanoma patients. The trial assessed the combination of the personalized mRNA cancer vaccine, Intismeran, and the immunotherapy drug Keytruda.
Patients who received both treatments after surgical removal of their tumors experienced a significantly longer period before cancer recurrence or metastasis compared to those who received only Keytruda. Specific efficacy data will be disclosed at an upcoming international conference.
The core of this treatment lies in the understanding that even within the same type of melanoma, the mutations in cancer cells can vary from patient to patient. Researchers analyze the surgically removed tumors to identify mutation proteins, known as neoantigens, that are present only in cancer cells. Based on this analysis, they create a tailored mRNA vaccine for each patient.
Once administered, the vaccine instructs cells to produce protein fragments resembling neoantigens, which immune cells recognize as markers of cancer cells. This process enables immune cells to identify and attack cancer cells exhibiting similar characteristics. Keytruda, administered alongside, acts as an immune checkpoint inhibitor that removes barriers preventing immune cells from attacking, allowing Intismeran to signal the targets for the immune response.
The personalized nature of this treatment is particularly advantageous for mRNA technology, which serves as a blueprint for instructing cells on which proteins to produce. This adaptability allows for easy modification to match the unique characteristics of each patient's cancer. The time required to analyze tumors and develop a suitable vaccine is approximately six weeks.
The growth potential of the mRNA therapeutic market is substantial. According to global market research firm Vision Research Reports, the global mRNA therapeutic market grew from $10.66 billion in 2024 to $12.31 billion last year. It is projected to reach $45.04 billion by 2034, with a compound annual growth rate (CAGR) of 15.5%.
The successful commercialization of COVID-19 mRNA vaccines has been a pivotal moment for the mRNA platform, demonstrating rapid development, production, and scalability within the global supply chain. This success has significantly increased trust in the efficiency and safety of mRNA technology. The report notes, "Clinical research on mRNA vaccines and combination therapies is expanding for major solid tumors such as lung, colorectal, and breast cancers."
Jung Yoon-taek, director of the Pharmaceutical Industry Strategy Research Institute, stated, "As the role of mRNA vaccines expands into therapeutics, there is now a motivation to diversify mRNA-based treatments." He added that competition among companies targeting various cancer types is expected to intensify.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.